The current travails of its US injectables subsidiary Sagent have not deterred Japan’s Nichi-Iko Pharmaceutical from setting ambitious growth targets for its overseas business. The generics specialist is also targeting a 15% share of its domestic market as it looks to promote its products in other Asian countries.
As it seeks to return Sagent to top-line growth in North America while it expands into other territories, Nichi-Iko has...




